Expression of receptor activator of nuclear factor κ-B ligand (RANKL) in neoplasms of dogs and cats

Journal of Veterinary Internal Medicine

Volumn 21, Issue 1, 2007, Pages 133-140

  Barger, Anne M ^a   Fan, Timothy M ^a   De Lorimier, Louis Philippe ^a   Sprandel, Ian T ^a   O'Dell Anderson, Kristen ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Bone pain; Cancer; Companion animals; Dual energy x ray absorptiometry; Immunocytochemistry; Malignant osteolysis

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL; ANIMAL DISEASE; ARTICLE; BONE DENSITY; BONE TUMOR; CAT; CAT DISEASE; CHONDROSARCOMA; DOG; DOG DISEASE; FEMALE; FIBROSARCOMA; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; OSTEOLYSIS; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANIMALS; BONE DENSITY; BONE NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CAT DISEASES; CATS; CELL LINE, TUMOR; CHONDROSARCOMA; DOG DISEASES; DOGS; FEMALE; FIBROSARCOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; OSTEOLYSIS; RANK LIGAND;

ANIMALIA; CANIS FAMILIARIS; FELIDAE;

EID: 33847082150     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2007)21[133:EORAON]2.0.CO;2     Document Type: Article

References (21)

1. Clohisy DR, Mantyh PW. Bone cancer pain and the role of RANKL/OPG. J Musculoskel Neuron Interact 2004;4:293-300.
2. Good CR, O'Keefe RJ, Puzas JE, Schwarz EM, Rosier RN. Immunohistochemical study of receptor activator of nuclear factor kappa-B ligand (RANK-L) in human osteolytic bone tumors. J Surg Oncol 2002;79:174-179.
3. Tada T, Jimi E, Okamoto M, Ozeki S, Okabe K. Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegrin expression in osteoblasts. Int J Cancer 2005;116:253-262.
4. Takayanagi H. Inflammatory bone destruction and osteoimmunology. J Periodontal Res 2005;40:287-293.
5. Nishimura M, Yuasa K, Mori K, et al. Cytological properties of stromal cells derived from giant cell tumor of bone (GCTSC) which can induce osteoclast formation of human blood monocytes without cell to cell contact. J Orthop Res 2005;23:979-987.
6. Roodman GD. Mechanisms of bone metastasis. N Eng J Med 2004;360:1655-1664.
7. Wittrant Y, Theoleyre S, Chipoy C, et al. RANKL/RANK/OPG: New therapeutic targets in bone tumors and associated osteolysis. Biochim Biophys Acta 2004;1704:49-57.
8. Roux S, Meignin V, Quillar J, et al. RANK (receptor activator of nuclear factor-kappa-B) and RANKL expression in multiple myeloma. Br J Haematol 2002;117:86-92.
9. Lee Y, Schwarz E, Davies M, et al. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res 2003;21:62-72.
10. Clines GA, Guise TA. Hypercalcemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 2005;12:549-583.
11. Body JJ, Fancon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, Denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-1228.
12. Kinpara K, Mogi M, Kuzushima M, Togari A. Osteoclast differentiation factor in human osteosarcoma cell line. J Immunoassay 2000;21:327-340.
13. Huang L, Cheng YY, Chow LTC, Zheng MH, Kumta SM. Tumour cells produce receptor activator of NF-κB ligand (RANKL) in skeletal metastases. J Clin Pathol 2002;55:876-879.
14. Yeung JS, Eton O, Buton DW, et al. Hypercalcemia due to parathyroid hormone-related protein secretion by melanoma. Horm Res 1998;49:288-291.
15. Bundred NJ. Osteolytic factor in breast tumor cells: Invited commentary. World J Surg 1995;19:297-298.
16. Zhang Y, Naoya F, Tomoko O, et al. Production of interleukin-11 in bone-derived endothelial cells and its role in the formation of osteolytic bone metastasis. Oncogene 1998;16:693-703.
17. Morinaga Y, Fujita N, Ohishi K, Tsuruo T. Stimulation of interleukin-11 production from osteoblast-like cells by transforming growth factor-β and tumor cell factors. Int J Cancer 1997;71:422-428.
18. Kobayashi A, Hirano F, Makino I. The inhibitory effect of bisphosphonates on glucocorticoid-induced RANKL expression in human cells. Scand J Rheumatol 2005;34:480-484.
19. Cui N, Numora T, Noma H, et al. Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice. Clin Cancer Res 2005;11:2713-2719.
20. Fan TM, de Lorimier LP, Charney SC, et al. Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement. J Vet Intern Med 2005;19:74-80.
21. Lacoste H, Fan TM, de Lorimier LP, et al. Urine N-telopeptide excretion in dogs with appendicular osteosarcoma. J Vet Intern Med 2006;20:335-341.